Klin Farmakol Farm. 2010;24(2):71-74

Future treatment of asthma

Vratislav Sedlák, Vladimír Koblížek
Plicní klinika FN Hradec Králové

Despite recent advances of pharmacological industry is asthma persisting severe symptomatic disease in subgroup of patients with

difficult-to-control asthma. This is a challenge for ongoing pharmacological research. The key solution for better outcome is to assess

phenotype of asthma carefully and combine anti-inflammatory therapies according to particular disease phenotype. This review summarizes

results of most promising anti-asthma drugs developed in the last years with presumption of early clinical application.

Keywords: new antiasthmatic, difficult to treat asthma, biological treatment of asthma

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sedlák V, Koblížek V. Future treatment of asthma. Klin Farmakol Farm. 2010;24(2):71-74.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. GINA, www.ginasthma.org.
    2. Sedlák V. Úskalí diagnostiky a léčby obtížně léčitelného astmatu. Acta pneumologica et phtiseologica.
    3. Diagnostický přístup k astmatu prizmatem eozinofilie a alergie Stud. Pneumol. Pthiseol. 69, 2009; 4: 130-139.
    4. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008; 121: 288-296. Go to original source... Go to PubMed...
    5. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788-797. Go to original source... Go to PubMed...
    6. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbation of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973-984. Go to original source... Go to PubMed...
    7. Nail P, Pizzichini MM, Kjasgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985-993. Go to original source... Go to PubMed...
    8. Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double blind, placebo-controlled study of tumor necrosis factor alpha in asthma. Am J Respir Crit Care Med 2006; 174: 753-762. Go to original source... Go to PubMed...
    9. Busse WW, Baker JW, Charous BL, et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma (abstract). J Allergy Clin Immunol 2004; 113: S286-S287. Go to original source...
    10. Brookman LJ, Knowles LJ, Barbier M, et al. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma. Curr Med Res Opin 2007; 23: 3113-3112. Go to original source... Go to PubMed...
    11. Nandeuil A, Kottakis I, Raptis H, et al. Safety and tolerability of the novel very long ?-2 agonist carmoterol given as 2 ug qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma. Abstract. Eur Respir J 2006; 28: 655.
    12. Cazzola M, Matera MG. Emerging inhaled bronchodilators: an update. Eur Respir. J 2009; 34: 757-769. Go to original source... Go to PubMed...
    13. Camoretti-Mercado B. Targeting the airway smooth muscle for asthma treatment. Translational Research 2009; 10: 165-174. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.